

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Introductory Chapter: Growth Disorders

Ahmed R.G.

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/intechopen.91661>

For most of the last decade, the field of growth disorders has evolved with more decisive signs of its detrimental potential to the health and development of fetuses, neonates, childhoods, and adults. This introductory chapter is, briefly, embracing themes on the growth disorders including growth hormone deficiency (GHD) and fetal growth restriction (intrauterine growth restriction (IUGR)). It then goes on to cover the effects of GHD or IUGR on different biological systems.

1. Harmful effects of GHD

The numerous actions of GH and insulin-growth factor-1 (IGF-1) play an important role in the health and development of offspring/individual [1–7]. The disorder in this axis/GHD during the development caused several complications including weight defect and developmental distortion [8–12]. A systemic GHD can induce hypersensitivity (mechanical and thermal) during the early postnatal period [13]. Also, GHD can decrease the minerals in bones and increase the risk of fracture in adults [14]. The harmful actions of GHD are reinforced in the presence of hypopituitarism [14–16].

2. IUGR and GH treatment (GHT)

On the other hand, IUGR disrupted the neurodevelopment processes (proliferation, migration, and maturation) [17–20]. IUGR/GHD can cause fetal small for gestational age (SGA) [21] and increase the risk of cardiovascular, renal, visual, and mental diseases [22]; diabetes mellitus/obesity (increase in fat mass) [23, 24]; metabolic inflammation [25]; liver dysfunction [26]; mitochondrial imbalance (impair oxygen transport capacity) [27]; or immune problems [28, 29]. Moreover, GHD can delay the development and maturation of the male reproductive system [30] and the female reproductive system [31, 32]. The GHT is more effective on the female fertility [31], sperm efficiency [33], and mood and cognitive behavior in patients with

GHD [34]. The outcome results of GHT depend on the age, gender, body mass index (BMI), muscle/bone index, and waist circumference. However, studies of possible effects of GHT on the gonads (sperm/ova quality) and fetal growth patterns in pregnancy are scarce.

Thus, the current *Growth Disorders* book will be of consciousness to scientists, embryologists, neuroendocrinologists, neurotoxicologists, and physicians coveting to follow recent publications in this field. This book explores in more detail the effects of GH and its deficiency on the brain, cardiovascular system, female gonadal system (ovarian functioning), liver, kidney, adrenal gland, skeletal muscles, bones, hematopoietic system, and gastrointestinal system in children and adults. Also, this book reviews the causes and diagnoses of fetal growth defect including IUGR and SGA. It describes the role of the pituitary/placental human GH (hGH) and IGF-1 gene family during pregnancy. Another theme of interest in this book is related to the impact of GH on germ cell development (proliferation, migration, and maturation), testicular development, pubertal maturation, testicular steroidogenesis, and erectile function. It follows the role of GH/Insulin/IGF-1 axis in the testicular activity. Finally, this book will discuss the impact of GH replacement therapy during pregnancy and its therapeutic potentials on reproductive health and male infertility.

Author details

Ahmed R.G.

Address all correspondence to: ahmedragab08@gmail.com

Division of Anatomy and Embryology, Faculty of Science, Zoology Department, Beni-Suef University, Beni-Suef, Egypt

References

- [1] Caicedo D, Díaz O, Devesa P, Devesa J. Growth hormone (GH) and cardiovascular system. *International Journal of Molecular Sciences*. 2018;**19**:pii. E290
- [2] Devesa J, Almengló C, Devesa P. Multiple effects of growth hormone in the body: Is it really the hormone for growth? *Clinical Medicine Insights: Endocrinology and Diabetes*. 2016;**9**:47-71
- [3] Laron Z, Galatzer A. Growth hormone, somatomedin and prolactin—Relationship to brain function. *Brain & Development*. 1985;**7**:559-567
- [4] Lobie PE, Garcia-Aragon J, Lincoln DT, Barnard R, Wilcox JN, Waters MJ. Localization and ontogeny of growth hormone receptor gene expression in the central nervous system. *Brain Research. Developmental Brain Research*. 1993;**74**:225-233
- [5] Mateus J, Newman RB, Zhang C, Pugh SJ, Grewal J, Kim S, et al. Fetal growth patterns in pregnancy-associated hypertensive disorders: NICHD Fetal Growth Studies. *American Journal of Obstetrics and Gynecology*. 2019;**221**:635.e1-635.e16

- [6] Neale J, Pais SMA, Nicholls D, Chapman S, Hudson LD. What are the effects of restrictive eating disorders on growth and puberty and are effects permanent? A systematic review and meta-analysis. *Journal of Adolescent Health*. 2020;**66**:144-156
- [7] Savaheli S, Ahmadiani A. Obsessive-compulsive disorder and growth factors: A comparative review. *Behavioural Brain Research*. 2019;**372**:111967
- [8] Ahmed RG, El-Gareib AW, Shaker HM. Gestational 3,3',4,4',5-pentachlorobiphenyl (PCB 126) exposure disrupts fetoplacental unit: Fetal thyroid-cytokines dysfunction. *Life Sciences*. 2018;**192**:213-220. DOI: 10.1016/j.lfs.2017.11.033
- [9] Ahmed RG, El-Gareib AW. Gestational arsenic trioxide exposure acts as a developing neuroendocrine-disruptor by downregulating Nrf2/PPAR γ and upregulating Caspase-3/NF- κ B/Cox2/BAX/iNOS/ROS. *Dose-Response*. 2019;**17**(2):1559325819858266. DOI: 10.1177/1559325819858266
- [10] Ahmed RG, El-Gareib AW. Maternal carbamazepine alters fetal neuroendocrine-cytokines axis. *Toxicology*. 2017;**382**:59-66. DOI: 10.1016/j.tox.2017.03.002
- [11] Ahmed RG. Gestational caffeine exposure acts as a fetal thyroid-cytokine disruptor by activating caspase-3/BAX/ Bcl-2/Cox2/NF- κ B at ED 20. *Toxicology Research*. 2019;**8**:196-205. DOI: 10.1039/c8tx00227d
- [12] Ahmed RG. Overdoses of acetaminophen disrupt the thyroid-liver axis in neonatal rats. *Endocrine, Metabolic & Immune Disorders Drug Targets*. 2019;**19**(5):705-714. DOI: 10.2174/1871530319666190212165603
- [13] Ford ZK, Dourson AJ, Liu X, Lu P, Green KJ, Hudgins RC, et al. Systemic growth hormone deficiency causes mechanical and thermal hypersensitivity during early postnatal development. *IBRO Reports*. 2019;**6**:111-121
- [14] Tritos NA. Focus on growth hormone deficiency and bone in adults. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2017;**31**:49-57
- [15] Vestergaard P, Jorgensen JO, Hagen C, et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas: a case-control study. *Clinical Endocrinology*. 2002;**56**:159-167
- [16] Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. *Journal of Bone and Mineral Research*. 2001;**16**:398-405
- [17] Dieni S, Rees S. Dendritic morphology is altered in hippocampal neurons following prenatal compromise. *Journal of Neurobiology*. 2003;**55**:41-52. DOI: 10.1002/neu.10194
- [18] Lister JP, Blatt GJ, DeBassio WA, Kemper TL, Tonkiss J, Galler JR, et al. Effect of protein malnutrition on numbers of neurons in the principal layers of the adult rat hippocampal formation. *Hippocampus*. 2005;**15**:393-403. DOI: 10.1002/hipo.20065
- [19] Mallard C, Loeliger M, Copolov D, Rees S. Reduced number of neurons in the hippocampus and the cerebellum in the postnatal guinea-pig following intrauterine growth-restriction. *Neuroscience*. 2000;**100**:327-333. DOI: 10.1016/S0306-4522(00)00271-2

- [20] Sizonenko SV, Borradori-Tolsa C, Bauthay DM, Lodygensky G, Lazeyras F, Huppi P. Impact of intrauterine growth restriction and glucocorticoids on brain development: Insights using advanced magnetic resonance imaging. *Molecular and Cellular Endocrinology*. 2006;**254-255**:163-171. DOI: 10.1016/j.mce.2006.04.035
- [21] de Bie HMA, Oostrom KJ, Delemarre-van de Waal HA. Brain development, intelligence and cognitive outcome in children born small for gestational age. *Hormone Research in Paediatrics*. 2010;**73**:6-14. DOI: 10.1159/000271911
- [22] Noeker M. Neurocognitive development in children experiencing intrauterine growth retardation and born small for gestational age: Pathological, constitutional and therapeutic pathways. *Hormone Research*. 2005;**64**(Suppl. 3):83-88. DOI: 10.1159/000089322
- [23] Beshyah SA, Freemantle C, Thomas E, et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. *Clinical Endocrinology*. 1995;**42**:179-189. DOI: 10.1111/j.1365-2265.1995.tb01860.x
- [24] Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. *Endocrine Reviews*. 2009;**30**:152-177. DOI: 10.1210/er.2008-0027
- [25] Höybye C, Faseh L, Himonakos C, Pielak T, Eugen-Olsen P. Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency. *Endocrine Connections*. 2019;**8**:772-779. DOI: 10.1530/EC-19-0159
- [26] Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. *European Journal of Endocrinology*. 2012;**167**:67-74. DOI: 10.1530/EJE-12-0252
- [27] Zueger T, Loher H, Egger A, Boesch C, Christ E. Regulation of fuel metabolism during exercise in hypopituitarism with growth hormone-deficiency (GHD). *Growth Hormone & IGF Research*. 2016;**29**:39-44
- [28] Sohmiya M, Kato Y. Effect of long-term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and haemoglobin levels in anaemic patients with adult GH deficiency. *Clinical Endocrinology*. 2001;**55**:749-754. DOI: 10.1046/j.1365-2265.2001.01417.x
- [29] Szalecki M, Malinowska A, Prokop-Piotrkowska M, Janas R. Interactions between the growth hormone and cytokines—A review. *Advances in Medical Sciences*. 2018;**63**:285-289
- [30] Bartlett JM, Charlton HM, Robinson IC, Nieschlag E. Pubertal development and testicular function in the male growth hormone-deficient rat. *The Journal of Endocrinology*. 1990;**126**:193-201. DOI: 10.1677/joe.0.1260193
- [31] Giampietro A, Milardi D, Bianchi A, Fusco A, Cimino V, Valle D, et al. The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: Report of four cases and review of the literature. *Fertility and Sterility*. 2009;**91**:390.e7-390.e11. DOI: 10.1016/j.fertnstert.2008.09.065

- [32] Spiliotis BE. Growth hormone insufficiency and its impact on ovarian function. *Annals of the New York Academy of Sciences*. 2003;**997**:77-84. DOI: 10.1196/annals.1290.009
- [33] Ovesen PG, Jørgensen JO, Ingerslev J, Orskov H, Christiansen JS. Growth hormone treatment of men with reduced sperm quality. *Ugeskrift for Laeger*. 1998;**160**:176-180
- [34] Butler T, Harvey P, Cardozo L, Zhu Y-S, Mosa A, Tanzi E, et al. Epilepsy, depression, and growth hormone. *Epilepsy & Behavior*. 2019;**94**:297-300. DOI: 10.1016/j.yebeh.2019.01.022

